Our findings argue that the novel anticancer effects of APG in lung cancer cells involve TRAIL sensitization through the augmented expression of its receptors via NF-κB downregulation and deactivation, JNK activation and the subsequent increase of p53. This evidence concerns the gene TP53 and lung carcinoma.